These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38367882)

  • 1. TDP-43-M323K causes abnormal brain development and progressive cognitive and motor deficits associated with mislocalised and increased levels of TDP-43.
    Godoy-Corchuelo JM; Ali Z; Brito Armas JM; Martins-Bach AB; García-Toledo I; Fernández-Beltrán LC; López-Carbonero JI; Bascuñana P; Spring S; Jimenez-Coca I; Muñoz de Bustillo Alfaro RA; Sánchez-Barrena MJ; Nair RR; Nieman BJ; Lerch JP; Miller KL; Ozdinler HP; Fisher EMC; Cunningham TJ; Acevedo-Arozena A; Corrochano S
    Neurobiol Dis; 2024 Apr; 193():106437. PubMed ID: 38367882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Motor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration.
    Riku Y; Iwasaki Y; Ishigaki S; Akagi A; Hasegawa M; Nishioka K; Li Y; Riku M; Ikeuchi T; Fujioka Y; Miyahara H; Sone J; Hattori N; Yoshida M; Katsuno M; Sobue G
    Brain; 2022 Aug; 145(8):2769-2784. PubMed ID: 35274674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum.
    Karch CM; Wen N; Fan CC; Yokoyama JS; Kouri N; Ross OA; Höglinger G; Müller U; Ferrari R; Hardy J; Schellenberg GD; Sleiman PM; Momeni P; Hess CP; Miller BL; Sharma M; Van Deerlin V; Smeland OB; Andreassen OA; Dale AM; Desikan RS;
    JAMA Neurol; 2018 Jul; 75(7):860-875. PubMed ID: 29630712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The vulnerability of motor and frontal cortex-dependent behaviors in mice expressing ALS-linked mutation in TDP-43.
    Wong P; Ho WY; Yen YC; Sanford E; Ling SC
    Neurobiol Aging; 2020 Aug; 92():43-60. PubMed ID: 32422502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modelling TDP-43 proteinopathy in Drosophila uncovers shared and neuron-specific targets across ALS and FTD relevant circuits.
    Godfrey RK; Alsop E; Bjork RT; Chauhan BS; Ruvalcaba HC; Antone J; Gittings LM; Michael AF; Williams C; Hala'ufia G; Blythe AD; Hall M; Sattler R; Van Keuren-Jensen K; Zarnescu DC
    Acta Neuropathol Commun; 2023 Oct; 11(1):168. PubMed ID: 37864255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TDP-43 pathology and functional deficits in wild-type and ALS/FTD mutant cyclin F mouse models.
    van Hummel A; Sabale M; Przybyla M; van der Hoven J; Chan G; Feiten AF; Chung RS; Ittner LM; Ke YD
    Neuropathol Appl Neurobiol; 2023 Apr; 49(2):e12902. PubMed ID: 36951214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43.
    Walker AK; Spiller KJ; Ge G; Zheng A; Xu Y; Zhou M; Tripathy K; Kwong LK; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2015 Nov; 130(5):643-60. PubMed ID: 26197969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuronal over-expression of Oxr1 is protective against ALS-associated mutant TDP-43 mislocalisation in motor neurons and neuromuscular defects in vivo.
    Williamson MG; Finelli MJ; Sleigh JN; Reddington A; Gordon D; Talbot K; Davies KE; Oliver PL
    Hum Mol Genet; 2019 Nov; 28(21):3584-3599. PubMed ID: 31642482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perfusion alterations converge with patterns of pathological spread in transactive response DNA-binding protein 43 proteinopathies.
    Ferraro PM; Jester C; Olm CA; Placek K; Agosta F; Elman L; McCluskey L; Irwin DJ; Detre JA; Filippi M; Grossman M; McMillan CT
    Neurobiol Aging; 2018 Aug; 68():85-92. PubMed ID: 29751289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible behavioral phenotypes in a conditional mouse model of TDP-43 proteinopathies.
    Alfieri JA; Pino NS; Igaz LM
    J Neurosci; 2014 Nov; 34(46):15244-59. PubMed ID: 25392493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel data-driven subtypes and stages of brain atrophy in the ALS-FTD spectrum.
    Shen T; Vogel JW; Duda J; Phillips JS; Cook PA; Gee J; Elman L; Quinn C; Amado DA; Baer M; Massimo L; Grossman M; Irwin DJ; McMillan CT
    Transl Neurodegener; 2023 Dec; 12(1):57. PubMed ID: 38062485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RRM adjacent TARDBP mutations disrupt RNA binding and enhance TDP-43 proteinopathy.
    Chen HJ; Topp SD; Hui HS; Zacco E; Katarya M; McLoughlin C; King A; Smith BN; Troakes C; Pastore A; Shaw CE
    Brain; 2019 Dec; 142(12):3753-3770. PubMed ID: 31605140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective Motor Neuron Resistance and Recovery in a New Inducible Mouse Model of TDP-43 Proteinopathy.
    Spiller KJ; Cheung CJ; Restrepo CR; Kwong LK; Stieber AM; Trojanowski JQ; Lee VM
    J Neurosci; 2016 Jul; 36(29):7707-17. PubMed ID: 27445147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders.
    Janssens J; Van Broeckhoven C
    Hum Mol Genet; 2013 Oct; 22(R1):R77-87. PubMed ID: 23900071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear transport dysfunction: a common theme in amyotrophic lateral sclerosis and frontotemporal dementia.
    Jovičić A; Paul JW; Gitler AD
    J Neurochem; 2016 Aug; 138 Suppl 1():134-44. PubMed ID: 27087014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes.
    Tan RH; Kril JJ; Fatima M; McGeachie A; McCann H; Shepherd C; Forrest SL; Affleck A; Kwok JB; Hodges JR; Kiernan MC; Halliday GM
    Brain; 2015 Oct; 138(Pt 10):3110-22. PubMed ID: 26231953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD.
    Kumar S; Phaneuf D; Cordeau P; Boutej H; Kriz J; Julien JP
    Mol Neurodegener; 2021 Jan; 16(1):1. PubMed ID: 33413517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice.
    Wu LS; Cheng WC; Shen CK
    J Biol Chem; 2012 Aug; 287(33):27335-44. PubMed ID: 22718760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An MND/ALS phenotype associated with C9orf72 repeat expansion: abundant p62-positive, TDP-43-negative inclusions in cerebral cortex, hippocampus and cerebellum but without associated cognitive decline.
    Troakes C; Maekawa S; Wijesekera L; Rogelj B; Siklós L; Bell C; Smith B; Newhouse S; Vance C; Johnson L; Hortobágyi T; Shatunov A; Al-Chalabi A; Leigh N; Shaw CE; King A; Al-Sarraj S
    Neuropathology; 2012 Oct; 32(5):505-14. PubMed ID: 22181065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy.
    Chew J; Cook C; Gendron TF; Jansen-West K; Del Rosso G; Daughrity LM; Castanedes-Casey M; Kurti A; Stankowski JN; Disney MD; Rothstein JD; Dickson DW; Fryer JD; Zhang YJ; Petrucelli L
    Mol Neurodegener; 2019 Feb; 14(1):9. PubMed ID: 30767771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.